<DOC>
	<DOCNO>NCT02959970</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics ( PK ) efficacy ACZONE Gel , 7.5 % administer topically once-daily 12 week 9 11 year-olds acne vulgaris .</brief_summary>
	<brief_title>Safety Efficacy Trial ACZONE ( Dapsone ) Gel , 7.5 % 9 11 Year-Old Patients With Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<criteria>Has acne vulgaris face , include nose , 20 100 total lesion ( noninflammatory and/or inflammatory ) . Has uncontrolled systemic disease ( ) Has severe cystic acne , acne conglobata , acne fulminans , secondary acne ( chloracne , druginduced acne ) Has use topical dapsone within 1 month prior screening Has use oral dapsone within 2 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>